Formulation and in vitro evaluation of crisaborole-loaded solid lipid nanoparticles - topical system for atopic dermatitis
DOI:
https://doi.org/10.69857/joapr.v14i2.1838Keywords:
Crisaborole, Solid Lipid Nanoparticles, Box–Behnken design, Atopic dermatitisAbstract
Background: Designing and testing a new way to deliver drugs through the skin using Solid Lipid Nanoparticles (SLNs) for sustained as well as enhanced topical delivery of Crisaborole. Methodology: Crisaborole was incorporated into SLNs using the Double Emulsification Solvent Evaporation Method. The SLNs were enhanced using a Box-Behnken design. The best-performing formulation was evaluated after optimization for particle size, etc, along with entrapment efficiency and in vitro release. Results: The SLNs exhibited a remarkable entrapment efficacy of 69.8 ± 1.1% to 80.6 ± 0.3%, and their particle size varied from 222.1 ± 8.5 nm to 440 ± 7.5 nm. In the in vitro release study of Crisaborole-SLNs, 92.7 ± 1.17 % was observed at 12 hours. The developed SLN formulation displays no significant change after three months of stability study under accelerated conditions. Conclusion: These results suggest that crisaborole-loaded solid lipid nanoparticles (SLNs) represent a promising vehicle for the topical delivery of crisaborole, with potential for enhanced dermal residence due to controlled release and nanoscale size within the skin, while minimizing systemic exposure.
Downloads
References
Langan SM, Irvine AD, Weidinger S, Flohr C, Silverberg JI, Deleuran M, et al. Atopic dermatitis. Lancet 396(10247) 345–360 (2020) https://doi.org/10.1016/S0140-6736(20)31286-1
Jeskey J, Brown K, Luger T, Simpson EL, Paller AS, Silverberg JI, et al. Atopic dermatitis: a review of diagnosis and treatment. J Pediatr Pharmacol Ther 29(6) 587–603 (2024) https://doi.org/10.5863/1551-6776-29.6.587
Maintz L, Novak N, Weidinger S, Werfel T, Bieber T, Wollenberg A, et al. From skin barrier dysfunction to systemic impact of atopic dermatitis: implications for a precision approach in dermocosmetics and medicine. J Pers Med 12(6) 893 (2022) https://doi.org/10.3390/jpm12060893
Liang J, Jin G, Liu Z, Wei J, Liang Y, Chen X, et al. Clinical characteristics and risk factors for mortality in cancer patients with COVID-19. Front Med 15(2) 264–274 (2021) https://doi.org/10.1007/s11684-021-0845-6
De Benedetto A, Kubo A, Beck LA, McGirt LY, Brunner PM, Guttman-Yassky E, et al. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 129(1) 14–30 (2009) https://doi.org/10.1038/jid.2008.259
Pariser DM. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther 16(3) 264–273 (2009)
Calabrese G, Campisi A, Brundo MV, Bonfiglio V, Carnazza ML, Graziano AC, et al. Topical and conventional systemic treatments in atopic dermatitis: have they gone out of fashion? Dermatol Pract Concept 12(1) e2022155 (2022) https://doi.org/10.5826/dpc.1201a155
Phalak P, Bhosale S, Yadav V, Reenu P, Ranaware S, Sharma A, et al. A systematic review on nano drug delivery system: solid lipid nanoparticles (SLN). Int J Curr Pharm Res 16(1) 10–20 (2024) https://doi.org/10.22159/ijcpr.2024v16i1.4020
Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Recent trends in nanocarriers for the management of atopic dermatitis. Pharm Nanotechnol 11(5) 397–409 (2023) https://doi.org/10.2174/2211738511666230330115229
Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 13(4) 288–303 (2018) https://doi.org/10.4103/1735-5362.235156
Paul DA, Nair AB, Shah J, Jacob S, Shinu P, Gupta S, et al. Design and optimization of acyclovir loaded solid lipid nanoparticles: a sustained release approach. Int J Appl Pharm 17(1) 355–364 (2024) https://doi.org/10.22159/ijap.2025v17i1.51877
Subroto E, Lestari D, Pratiwi A, Lestari S, Hartono Y, Suryani S, et al. Solid lipid nanoparticles: review of the current research on encapsulation and delivery systems for active and antioxidant compounds. Antioxidants 12(3) 633 (2023) https://doi.org/10.3390/antiox12030633
Becker Peres L, Becker Peres L, Araújo PHH, Sayer C, et al. Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique. Colloids Surf B Biointerfaces 140 317–323 (2016) https://doi.org/10.1016/j.colsurfb.2015.12.033
Cunha S, Costa CP, Moreira JN, Lobo JMS, Silva AC, et al. Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: a review. Nanomedicine 28 102206 (2020) https://doi.org/10.1016/j.nano.2020.102206
Agarwal P, Bakshi V. Development of gabapentin-loaded solid lipid nanoparticle for alleviating seizure activity in picrotoxin and bicuculline-induced rats. Int J Appl Pharm 16(6) 224–237 (2024) https://doi.org/10.22159/ijap.2024v16i6.51157
Cassayre M, Teles de Souza D, Claeys-Bruno M, Altié A, Piccerelle P, Sauzet C. Optimization of solid lipid nanoparticle formulation using design of experiments, part I: strategic tool for the determination of critical parameters regarding formulation and process. Nanomaterials 15(13) 1034 (2025) https://doi.org/10.3390/nano15131034
Malatesta M. Transmission electron microscopy as a powerful tool to investigate the interaction of nanoparticles with subcellular structures. Int J Mol Sci 22(23) 12789 (2021) https://doi.org/10.3390/ijms222312789
Chen C, Zhang Y, Li M, Wang X, Liu H, Zhao Y, et al. Characterization of lipid-based nanomedicines at the single-particle level. Fundam Res 3(4) 488–504 (2022) https://doi.org/10.1016/j.fmre.2022.09.011
Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10(2) 57 (2018) https://doi.org/10.3390/pharmaceutics10020057
Onugwu AL, Nwankwo EE, Ugwu CE, Okafor IS, Attama AA, et al. Development and optimization of solid lipid nanoparticles coated with chitosan and poly(2-ethyl-2-oxazoline) for ocular drug delivery of ciprofloxacin. J Drug Deliv Sci Technol 74 103527 (2022) https://doi.org/10.1016/j.jddst.2022.103527
Shah M, Pathak K, et al. Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride. Indian J Pharm Sci 74(5) 434–442 (2012) https://doi.org/10.4103/0250-474X.108419
Sandhu SK, Bilandi A, Kumar S, Kapoor B, Kataria MK, et al. Systematic development and characterization of novel, high drug-loaded, photostable, curcumin solid lipid nanoparticle hydrogel for wound healing. Antioxidants 10(5) 725 (2021) https://doi.org/10.3390/antiox10050725
Singh C, Rao K, Yadav N, Bansal N, Vashist Y, Kumari S, et al. A review: drug excipient incompatibility by FTIR spectroscopy. Curr Pharm Anal 19(5) e280223214105 (2023) https://doi.org/10.2174/1573412919666230228102158
Bhalekar MR, Pokharkar V, Madgulkar A, et al. Formulation of piperine solid lipid nanoparticles (SLN) for treatment of rheumatoid arthritis. Drug Dev Ind Pharm 43(6) 1003–1010 (2017) https://doi.org/10.1080/03639045.2017.1291666
Thatipamula RP, Palem CR, Gannu R, Mudragada S, Yamsani MR, et al. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. DARU J Pharm Sci 19(1) 23–32 (2011)
Barot M, Patel D, Shah K, Mehta P, Joshi R, Patel H, et al. Formulation development and evaluation of proniosomal gel containing crisaborole. Res J Pharm Technol 18(5) 2261–2268 (2025) https://doi.org/10.52711/0974-360X.2025.00324
Souto EB, Doktorovova S, Campos JR, Martins-Gomes C, Silva AM, et al. Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. Heliyon 8(2) e08938 (2022) https://doi.org/10.1016/j.heliyon.2022.e08938
Safta DA, Vlase L, Toma CC, et al. SLNs and NLCs for skin applications: enhancing the bioavailability of natural bioactives. Pharmaceutics 16(10) 1270 (2024) https://doi.org/10.3390/pharmaceutics16101270
Altun E, Yuca E, Ekren N, Kalaskar DM, Ficai D, Dolete G, et al. Kinetic release studies of antibiotic patches for local transdermal delivery. Pharmaceutics 13(5) 613 (2021) https://doi.org/10.3390/pharmaceutics13050613
Madan JR, Khude PA, Dua K, et al. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int J Pharm Investig 4(2) 60–64 (2014) https://doi.org/10.4103/2230-973X.133047
Makoni PA, Kasongo KW, Walker RB, et al. Short term stability testing of efavirenz-loaded solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions. Pharmaceutics 11(8) 397 (2019) https://doi.org/10.3390/pharmaceutics11080397
Fantini A, Sinico C, et al. In vitro skin retention of crisaborole after topical application. Pharmaceutics 12(6) 491 (2020) https://doi.org/10.3390/pharmaceutics12060491
Ghasemiyeh P, Mohammadi-Samani S. Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: advantages and disadvantages. Drug Des Devel Ther 14 3271–3289 (2020) https://doi.org/10.2147/DDDT.S264648
Concini A, et al. Ex-vivo skin retention of crisaborole from microemulsion and micellar formulations. J Drug Deliv Sci Technol 100 106082 (2024) https://doi.org/10.1016/j.jddst.2024.106082
Subroto E, Lestari D, Pratiwi A, Lestari S, Hartono Y, Suryani S, et al. Solid lipid nanoparticles: review of the current research on encapsulation and delivery systems for active and antioxidant compounds. Antioxidants 12(3) 633 (2023) https://doi.org/10.3390/antiox12030633
Gupta B, Sharma R. Formulation and in vitro characterization of the solid lipid nanoparticles of naftopidil for enhancing oral bioavailability. Asian J Pharm Clin Res 16(2) 77–82 (2023) https://doi.org/10.22159/ajpcr.2023.v16i2.46465
Published
How to Cite
Issue
Section
Copyright (c) 2026 Nisha V Kalayil, Tularam Barot, Aarati Budar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
